Company news

MaxCyte, Inc. news in 2024

MaxCyte, Inc.'s news releases, calls and decks from 2024, newest first.

View company

MaxCyte Announces Retirement of Board Member Art Mandell

December 21, 2024

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

December 7, 2024

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

November 12, 2024

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

November 5, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors

October 14, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

October 9, 2024

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

September 14, 2024

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

August 5, 2024

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 21, 2024

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

May 6, 2024

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

April 9, 2024

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

April 1, 2024

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

March 11, 2024

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

March 3, 2024

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

February 8, 2024

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

January 29, 2024

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

January 22, 2024

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

January 7, 2024

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

December 31, 2023

Calls in 2024

Decks in 2024